<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B200B50D-C8FA-4FF0-A901-53A759FE1251"><gtr:id>B200B50D-C8FA-4FF0-A901-53A759FE1251</gtr:id><gtr:name>Bigdna Ltd</gtr:name><gtr:address><gtr:line1>THE WALLACE BUILDING , ROSLIN BIOCENTRE</gtr:line1><gtr:city>ROSLIN</gtr:city><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B200B50D-C8FA-4FF0-A901-53A759FE1251" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B200B50D-C8FA-4FF0-A901-53A759FE1251</gtr:id><gtr:name>Bigdna Ltd</gtr:name><gtr:address><gtr:line1>THE WALLACE BUILDING , ROSLIN BIOCENTRE</gtr:line1><gtr:city>ROSLIN</gtr:city><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>95000.0</gtr:offerGrant><gtr:projectCost>161190.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1BDA08F2-C102-4A56-905D-D4646C403770"><gtr:id>1BDA08F2-C102-4A56-905D-D4646C403770</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>March</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710296"><gtr:id>58EE8F2A-478D-4569-913A-C955384688B5</gtr:id><gtr:title>Optimisation of bacteriophage M13-based DNA and chimeric (DNA/ protein) vaccines</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710296</gtr:grantReference><gtr:abstractText>Bacteriophage (phage) offer the potential to deliver both protein and DNA vaccines within the
same construct. They also promise extremely rapid development and manufacturing
timescales, since the DNA vaccine cassette can be synthesised to express antigens for
virtually any pathogen, literally within days following sequence identification. Phage are
extremely robust, and can be delivered orally or in combination with other vaccines, and
being particulate antigens, are naturally targeted to antigen presenting cells.
BigDNA holds patents surrounding bacteriophage-based DNA and DNA/protein (chimeric)
vaccines. To date, our focus has been on using bacteriophage lambda. The company now
wishes to explore the potential for using phage M13 as an alternative vehicle for this
technology. M13 is extremely well characterised with an excellent manufacturing base, and
offers enormous technological potential. Phage-based DNA vaccine technology has been
developed and patented by BigDNA in the UK, and has already attracted overseas investment,
commercial collaborative R &amp;amp; D activity, and a licensing agreement with big pharma.
This project aims to investigate the potential of a range of modifications designed to optimise
and develop M13 as a platform for this purpose which should result in a vaccine platform and
products capable of addressing a wide range of infectious diseases and cancers for which
current vaccines either do not exist, or alternatively, cannot be developed in the rapid
timescales likely required for pandemic disease indications.</gtr:abstractText><gtr:fund><gtr:end>2014-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>95000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710296</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>